Meribank Biotech , Ltd Return on Equity

Meribank Biotech , Ltd (4724.TWO) currently reports a ROE of -17.14%. That is above the Healthcare sector average of -75.59%. Use the charts on this page to explore Meribank Biotech , Ltd's ROE history and peer comparisons.

Meribank Biotech , Ltd's ROE of -17.14% is higher than the Healthcare sector average of -75.59%. That is roughly 77.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Meribank Biotech , Ltd's current -17.14% should be judged against Healthcare norms (sector average: -75.59%) and against 4724.TWO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -17.14%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.59%. From there, open related valuation or income-statement pages for Meribank Biotech , Ltd, and consider following 4724.TWO for alerts when major investors trade the stock.

Meribank Biotech , Ltd is classified in the Healthcare sector. On ROE, it currently shows -17.14% versus a sector average near -75.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 4724.TWO with unrelated industries.